Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04666688 · ClinicalTrials.gov registry record · Phase 1
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study of Colorectal Cancer and Pancreatic Cancer, sponsored by PureTech.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 12
- Study locations
NCT04666688 is a Phase 1 study of Colorectal Cancer and Pancreatic Cancer that has completed, run by PureTech. The registered enrollment target is 44 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (97% lower). The trial reports 12 study locations across 8 states.
The verdict
NCT04666688, a Phase 1 study of Colorectal Cancer and Pancreatic Cancer, has completed, sponsored by PureTech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 12
- Study locations
Study Summary
A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors
Conditions Studied
Interventions
- DRUG Tislelizumab
- DRUG LYT-200
- DRUG Gemcitabine/nab-paclitaxel
Study Locations (12)
Colorado
- University of Colorado Hospital - Denver
- Sarah Cannon Research Institute at Health One - Denver
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
New York
- Columbia University - New York
- Memorial Sloan-Kettering Cancer Center - New York
Texas
- University of Texas, M.D. Anderson Cancer Center - Houston
- South Texas Accelerated Research Therapeutics - San Antonio
California
- UCLA - Los Angeles
Florida
- Sarah Cannon Research Institute, Florida Cancer Specialists - Sarasota
Michigan
- South Texas Accelerated Research Therapeutics - Grand Rapids
Tennessee
- Sarah Cannon Research Institute, Tennessee Oncology - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2020-12-15 |
| Est. Completion | 2024-12-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04666688
The ClinicalTrials.gov registry entry for NCT04666688 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (97% lower). The listed sponsor is PureTech, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Tislelizumab is the first listed.
NCT04666688 reports 12 study locations spanning 8 distinct geographic areas - top geographies include Colorado, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT04666688 about?
NCT04666688 is a clinical study titled "LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors". A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors
What is the current status of trial NCT04666688?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2020-12-15. Estimated completion is 2024-12-12.
What conditions does trial NCT04666688 study?
This clinical trial studies the following conditions: Colorectal Cancer, Pancreatic Cancer, Head and Neck Cancer, Solid Tumor, Metastatic Cancer.
What interventions are being tested in trial NCT04666688?
The interventions under investigation include: Tislelizumab (DRUG), LYT-200 (DRUG), Gemcitabine/nab-paclitaxel (DRUG).
Who is sponsoring clinical trial NCT04666688?
This trial is sponsored by PureTech, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04666688 being conducted?
This trial has 12 study locations across California, Colorado, Florida, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.